Minimally invasive image-guided therapies for hepatocellular carcinoma

Minimally invasive image-guided therapies for hepatocellular carcinoma Mohamed E Abdelsalam,1 Ravi Murthy,1 Rony Avritscher,1 Armeen Mahvash,1 Michael J Wallace,1 Ahmed O Kaseb,2 Bruno C Odisio,1 1Department of Interventional Radiology, 2Department of Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Abstract: Hepatocellular carcinoma (HCC) is the fifth most frequently occurring cancer globally and predominantly develops in the setting of various grades of underlying chronic liver disease, which affects management decisions. Image-guided percutaneous ablative or transarterial therapies have acquired wide acceptance in HCC management as a single treatment modality or combined with other treatment options in patients who are not amenable for surgery. Recently, such treatment modalities have also been used for bridging or downsizing before definitive treatment (ie, surgical resection or liver transplantation). This review focuses on the use of minimally invasive image-guided locoregional therapies for HCC. Additionally, it highlights recent advancements in imaging and catheter technology, embolic materials, chemotherapeutic agents, and delivery techniques; all lead to improved patient outcomes, thereby increasing the interest in these invasive techniques. Keywords: hepatocelleular carcinoma, locoregional therapy, TACE, ablation, 90Y